Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Avience Biomedicals Limited (NSE: AVIENCE), ISIN INE0V9I01017 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
AVIENCE last traded at ₹274.50 (-0.76%), with a 52-week range of ₹222.00 to ₹414.95 (as of 9 Oct 2026).
Shareholding as of Jun 2026: promoters 64.59%, FIIs 3.06%, DIIs 9.08%, mutual funds 0.25%.
EquiSense Score (ECS): 62/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.